Review article · 2025 · Open access
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007 · Published 1 March 2025 · DOI 10.1002/wnan.70007
In brief
“Engineering Lipid Nanoparticles for mRNA Immunotherapy” is a 2025 review article by Robby C. Zwolsman and 3 co-authors, published in Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. OpenAlex counts 43 citations as of 21 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology.
- Citations
- 43
- Most cited in
- 2026 (31)
- Field-weighted impact
- 2.69
- References
- 210
- Authors
- 4
Abstract
Over the last decades, messenger RNA (mRNA) has emerged as a promising therapeutic modality, enabling the delivery of genetic instructions to cells for producing therapeutic proteins or antigens. As such, mRNA-based therapies can be developed for a wide range of conditions, including infections, cancer, metabolic disorders, and genetic diseases. Nevertheless, using mRNA therapeutically requires chemical modifications to reduce immunostimulatory effects and nanotechnology to prevent degradation and ensure intracellular delivery. Lipid nanoparticles (LNPs) have become the most effective delivery platform for mRNA therapeutics, which are primarily employed for vaccine purposes following local administration and hepatic applications following systemic administration. Here, we review the state-of-the-art LNP-mRNA technology and discuss its potential for immunotherapy. We first outline the requirements for mRNA to be used therapeutically, including the role of LNP-mediated delivery. Next, we highlight LNP-mRNA immunotherapy approaches for vaccination, immuno-oncology, and autoimmune disorders. In addition, we discuss challenges that are limiting LNP-mRNA's widespread use, including tunable biodistribution and immunostimulatory effects. Finally, we provide an outlook on how implementing approaches such as library screening and machine learning will guide the development of next-generation mRNA therapeutics.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025). Engineering Lipid Nanoparticles for mRNA Immunotherapy. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007. https://doi.org/10.1002/wnan.70007
MLA 9
Zwolsman, Robby C., et al. “Engineering Lipid Nanoparticles for mRNA Immunotherapy.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 17, no. 2, 2025, p. e70007. https://doi.org/10.1002/wnan.70007.
Chicago
Zwolsman, Robby C., Youssef Bahaaeldin Darwish, Ewelina Kluza, and Roy van der Meel. 2025. “Engineering Lipid Nanoparticles for mRNA Immunotherapy.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 17 (2): e70007. https://doi.org/10.1002/wnan.70007.
Harvard
Zwolsman, R. C. et al. (2025) ‘Engineering Lipid Nanoparticles for mRNA Immunotherapy’, Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), p. e70007. doi:10.1002/wnan.70007.
IEEE
R. C. Zwolsman, Y. B. Darwish, E. Kluza, and R. van der Meel, “Engineering Lipid Nanoparticles for mRNA Immunotherapy,” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 17, no. 2, p. e70007, 2025, doi: 10.1002/wnan.70007.
BibTeX
@article{zwolsman2025engineering,
title = {{Engineering Lipid Nanoparticles for mRNA Immunotherapy}},
author = {Zwolsman, Robby C. and Darwish, Youssef Bahaaeldin and Kluza, Ewelina and van der Meel, Roy},
journal = {Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology},
year = {2025},
volume = {17},
number = {2},
pages = {e70007},
doi = {10.1002/wnan.70007},
url = {https://doi.org/10.1002/wnan.70007}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- lipid nanoparticles
- mRNA therapeutics
- mRNA delivery
- mRNA vaccines
- cancer immunotherapy
- autoimmune disease
- immunostimulatory effects
- tissue distribution
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025). Engineering Lipid Nanoparticles for mRNA Immunotherapy. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 17(2), e70007. https://doi.org/10.1002/wnan.70007
How many times has this paper been cited?
43 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology: sign in and open the full text from this page.
Who wrote this paper?
Robby C. Zwolsman, Youssef Bahaaeldin Darwish, Ewelina Kluza, Roy van der Meel.
What is the DOI of this paper?
10.1002/wnan.70007, permanently at https://doi.org/10.1002/wnan.70007. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.